ScripBiotech valuations and funding availability went into reverse in the second half of 2021, following a period of abundant financing. Meanwhile, big pharma companies face their own problems, with many b
ScripHalozyme Therapeutics is pulling back from its attempt to acquire Evotec after the German service provider appeared uninterested in the offer, though Halozyme remains convinced that the two firms are
In VivoWith the business year almost complete, a review of biopharmaceutical dealmaking showed that Novartis, in particular, enjoyed a very productive year with 21 transactions overall, including six acquisi
ScripShares in Germany’s Evotec are on the rise thanks to an unsolicited takeover bid from Halozyme Therapeutics but the size of the offer – around €2.00bn ($2.12bn) – suggests that any potential deal is s